MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
45.28
+0.49
+1.09%
After Hours: 45.28 0 0.00% 17:33 02/06 EST
OPEN
45.94
PREV CLOSE
44.79
HIGH
46.66
LOW
43.94
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
57.99
52 WEEK LOW
24.10
MARKET CAP
4.64B
P/E (TTM)
-9.9894
1D
5D
1M
3M
1Y
5Y
1D
Crinetics Pharmaceuticals Participates in TD Cowen and Leerink Investor Conferences
Reuters · 1d ago
Crinetics Pharmaceuticals nimmt an zwei großen Investorenkonferenzen teil
Reuters · 1d ago
Weekly Report: what happened at CRNX last week (0126-0130)?
Weekly Report · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK)
TipRanks · 01/30 12:30
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Gilead Sciences (GILD)
TipRanks · 01/29 13:02
Add Up The Parts: IHE Could Be Worth $96
NASDAQ · 01/29 12:07
Crinetics Pharmaceuticals Inc. to Report Fourth Quarter and Full Year 2025 Financial Results
Reuters · 01/26 22:00
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Barchart · 01/26 16:00
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.